Drug Profile
Idecabtagene vicleucel - 2seventy bio
Alternative Names: Abecma; Anti-BCMA CART Cell Therapy - bluebird bio/Celgene; Anti-BCMA CART cells - bluebird bio/Celgene; bb-2121; BMS-986395; ide-celLatest Information Update: 10 Apr 2024
Price :
$50
*
At a glance
- Originator bluebird bio
- Developer 2seventy bio; bluebird bio; Bristol-Myers Squibb; Celgene Corporation
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Multiple myeloma
Most Recent Events
- 04 Apr 2024 The approved label for idecabtagene vicleucel cytokine release syndrome, neurologic toxicities, hemophagocytic lymphohistiocytosis/macrophage activation syndrome, prolonged cytopenia, and secondary hematological malignancies carries a black box warning
- 04 Apr 2024 US FDA approves idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy in USA
- 20 Mar 2024 European Commission approves Idecabtagene vicleucel for Multiple myeloma (Second-line therapy or greater, for patients who have received at least two prior therapies) in European Union, Liechtenstein, Norway and Iceland